Major histocompatibility complex–peptide–T cell receptor complex (MHC–peptide–TCR complex)

The major histocompatibility complex–peptide–T cell receptor complex is a transient, multisubunit assembly at the heart of adaptive cellular immunity. It forms when a T cell receptor (TCR) on the surface of a T lymphocyte specifically binds to a short peptide antigen presented by a major histocompatibility complex (MHC) molecule, typically on an antigen-presenting cell. This recognition event initiates transmembrane signaling, activating the T cell and orchestrating downstream immune responses[1][4][6]. MHC molecules (called human leukocyte antigens, HLA, in humans) are highly polymorphic proteins classified as class I (recognizing CD8+ T cells, presenting shorter peptides) and class II (for CD4+ T cells, presenting longer peptides)[1][3]. The diversity of TCRs, generated through V(D)J recombination, enables the immune system to recognize myriad peptide–MHC combinations[2][5]. Structural studies reveal that the TCR binds the peptide–MHC complex using complementarity-determining regions (CDRs), with canonical docking geometry governing antigen recognition and specificity[5][6]. The specificity and stability of this complex underpin its central role in immune defense, but cross-reactivity can risk autoimmunity[1]. Therapeutically, interventions target either the peptide–MHC complex, the TCR, or the interface between them, for cancer immunotherapy, infectious disease, and autoimmunity[6]. The complex itself is not a single, druggable molecule but a molecular interface fundamental to antigen-specific T cell function.

Other names

MHC–peptide–TCR complexpMHC–TCR complexpeptide–MHC–TCR ternary complexTCR–pMHC complexTCR–MHC–peptide complex

Blockade/disruption of MHC–peptide–TCR binding to suppress T cell activity (autoimmunity/allergy) Enhancement or redirection of TCR recognition of specific pMHC (anti-tumor or anti-infective adoptive cell therapies) Immune monitoring (using pMHC tetramers to detect antigen-specific T cells)